Clinical trial / 2019
Supplementation with marine n-3 fatty acids did not reduce the incidence of major cardiovascular events or invasive cancer compared with placebo.
In the VITAL trial, 25,871 participants were randomized to 1 g per day of marine n-3 fatty acids or placebo (alongside vitamin D3 in a 2x2 factorial design) with a median follow-up of 5.3 years. Marine n-3 fatty acid supplementation did not significantly lower major cardiovascular events (HR, 0.92; 95% CI, 0.80 to 1.06; P=0.24) or invasive cancer (HR, 1.03; 95% CI, 0.93 to 1.13; P=0.56). For secondary endpoints, total myocardial infarction was lower in the n-3 group (HR, 0.72; 95% CI, 0.59 to 0.90), but stroke, cancer death, and all-cause death showed no significant differences. No excess risks of bleeding or other serious adverse events were observed.
- Study type
- Randomized, placebo-controlled, 2x2 factorial trial
- Who was studied
- 25,871 US men aged >=50 and women aged >=55 (including 5,106 Black participants)
- What was measured
- Major cardiovascular events and invasive cancer of any type
THE PAPER
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, VITAL Research Group. N Engl J Med, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.